Supramolecular cyclodextrin complex: Diversity, safety, and applications in ocular therapeutics

Chaudhari, Pinal and Ghate, Vivek M and Lewis, Shaila Angela (2019) Supramolecular cyclodextrin complex: Diversity, safety, and applications in ocular therapeutics. Experimental Eye Research, 189. pp. 1-11. ISSN 0014-4835

[img] PDF
RMS - 00007843.pdf - Published Version
Restricted to Registered users only

Download (927kB) | Request a copy


Approximately 30–70% of the existing and new chemical entities exhibit poor aqueous solubility. For topical ocular delivery, drug molecules need to possess both hydrophilic and lipophilic nature to enable absorption through the aqueous tear layer and permeation through the corneal lipophilic barrier. To overcome the aqueous solubility related issues, various techniques such as solid dispersion, particle size reduction, cyclodextrin complexation, co-solvency, prodrug, derivatization, and salt formation are being explored in the healthcare sector. Cyclodextrin inclusion complexation techniques have been established by several pharmaceutical industries for systemic administration allowing a transition from the lab to the clinics. Though cyclodextrins are exploited in ocular drug delivery, there are prevailing concerns regarding its absorption enhancing capacity and mechanism, retention at the ocular surfaces and, irritation and toxicity profiles. In the present review, the efforts taken by various research groups to address the concerns of using cyclodextrin and its derivatives in ocular therapeutics are summarized. Also, considerations and utility of cyclodextrin systems in fabricating newer formulations such as contact lens, inserts, and implants have been discussed in the review.

Item Type: Article
Uncontrolled Keywords: Cyclodextrin; inclusion complexes; ocular diseases; Topical delivery; toxicity; mechanism.
Subjects: Pharmacy > MCOPS Manipal > Pharmaceutics
Depositing User: KMC Library
Date Deposited: 24 Jan 2020 13:56
Last Modified: 24 Jan 2020 13:56

Actions (login required)

View Item View Item